Logo image of XLO

XILIO THERAPEUTICS INC (XLO) Stock Fundamental Analysis

NASDAQ:XLO - Nasdaq - US98422T1007 - Common Stock - Currency: USD

0.663  +0 (+0.45%)

Fundamental Rating

2

XLO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. The financial health of XLO is average, but there are quite some concerns on its profitability. XLO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XLO has reported negative net income.
In the past year XLO had a positive cash flow from operations.
XLO had negative earnings in each of the past 5 years.
XLO had a negative operating cash flow in each of the past 5 years.
XLO Yearly Net Income VS EBIT VS OCF VS FCFXLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of XLO (-52.36%) is comparable to the rest of the industry.
With a Return On Equity value of -507.50%, XLO is not doing good in the industry: 77.86% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -52.36%
ROE -507.5%
ROIC N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XLO Yearly ROA, ROE, ROICXLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XLO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XLO Yearly Profit, Operating, Gross MarginsXLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

XLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
XLO has more shares outstanding than it did 1 year ago.
XLO has more shares outstanding than it did 5 years ago.
XLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XLO Yearly Shares OutstandingXLO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XLO Yearly Total Debt VS Total AssetsXLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -6.34, we must say that XLO is in the distress zone and has some risk of bankruptcy.
XLO has a Altman-Z score of -6.34. This is in the lower half of the industry: XLO underperforms 65.70% of its industry peers.
There is no outstanding debt for XLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -6.34
ROIC/WACCN/A
WACC10.89%
XLO Yearly LT Debt VS Equity VS FCFXLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

XLO has a Current Ratio of 1.96. This is a normal value and indicates that XLO is financially healthy and should not expect problems in meeting its short term obligations.
XLO's Current ratio of 1.96 is on the low side compared to the rest of the industry. XLO is outperformed by 76.95% of its industry peers.
XLO has a Quick Ratio of 1.96. This is a normal value and indicates that XLO is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of XLO (1.96) is worse than 75.14% of its industry peers.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.96
XLO Yearly Current Assets VS Current LiabilitesXLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

XLO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.32%, which is quite impressive.
EPS 1Y (TTM)67.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, XLO will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.00% on average per year.
XLO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.36% yearly.
EPS Next Y51.87%
EPS Next 2Y16.99%
EPS Next 3Y0.45%
EPS Next 5Y18%
Revenue Next Year226.32%
Revenue Next 2Y82.33%
Revenue Next 3Y49.24%
Revenue Next 5Y5.36%

3.3 Evolution

XLO Yearly Revenue VS EstimatesXLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
XLO Yearly EPS VS EstimatesXLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XLO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XLO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XLO Price Earnings VS Forward Price EarningsXLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

100.00% of the companies in the same industry are more expensive than XLO, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 1.63
EV/EBITDA N/A
XLO Per share dataXLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.99%
EPS Next 3Y0.45%

More info and screens

0

5. Dividend

5.1 Amount

XLO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XILIO THERAPEUTICS INC

NASDAQ:XLO (8/8/2025, 4:11:42 PM)

0.663

+0 (+0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners40.58%
Inst Owner Change0%
Ins Owners0.55%
Ins Owner Change0.78%
Market Cap34.33M
Analysts80
Price Target4.08 (515.38%)
Short Float %11.93%
Short Ratio5.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-139.49%
Min EPS beat(2)-287.6%
Max EPS beat(2)8.61%
EPS beat(4)2
Avg EPS beat(4)-67.65%
Min EPS beat(4)-287.6%
Max EPS beat(4)11.7%
EPS beat(8)5
Avg EPS beat(8)-85.3%
EPS beat(12)7
Avg EPS beat(12)-56.16%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-41.17%
Min Revenue beat(2)-48.27%
Max Revenue beat(2)-34.07%
Revenue beat(4)0
Avg Revenue beat(4)-51.67%
Min Revenue beat(4)-92.22%
Max Revenue beat(4)-32.1%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)48.98%
EPS NY rev (1m)0%
EPS NY rev (3m)-64.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-47.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.7
P/FCF 1.63
P/OCF 1.63
P/B 3.21
P/tB 3.21
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)0.41
FCFY61.3%
OCF(TTM)0.41
OCFY61.47%
SpS0.18
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.36%
ROE -507.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 226.91%
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 3.42%
Cap/Sales 0.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.96
Quick Ratio 1.96
Altman-Z -6.34
F-Score6
WACC10.89%
ROIC/WACCN/A
Cap/Depr(3y)42.95%
Cap/Depr(5y)81.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.97%
EPS Next Y51.87%
EPS Next 2Y16.99%
EPS Next 3Y0.45%
EPS Next 5Y18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year226.32%
Revenue Next 2Y82.33%
Revenue Next 3Y49.24%
Revenue Next 5Y5.36%
EBIT growth 1Y21.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.76%
EBIT Next 3Y9.46%
EBIT Next 5Y12.01%
FCF growth 1Y125.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y126.34%
OCF growth 3YN/A
OCF growth 5YN/A